Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.

Urology - 1 Dec 2007

Satoh Makoto, Wang Hua, Ishidoya Shigeto, Abe Hisashi, Moriya Takuya, Hamada Hirofumi, Arai Yoichi

Abstract excerpt

OBJECTIVES: To report our therapeutic results in prostate cancer using double-mutated adenovirus AxdAdB-3, which has a mutation of E1A and deletion of E1B 55KD. Advanced prostate cancer can harbor multiple genetic alterations, including p53 and Rb/E2F/p16, and is often refractory to hormonal abla...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Adenovirus E1A Proteins
Share to Cytopathogenic Effect, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Transfer Techniques

Share to Mice, SCID

Share to Oncolytic Virotherapy

Share to Prostatic Neoplasms

Share to Receptors, Virus

Source

Identifiers

PMID: 18158069
DOI: 10.1016/j.urology.2007.09.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18158069-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.PMID 18158069Read ↗

Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.Semantic proximity Read ↗

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.Semantic proximity Read ↗

Targeting Gene‐ViroTherapy for prostate cancer by DD3‐driven oncolytic virus‐harboring interleukin‐24 geneSemantic proximity Read ↗

Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.Semantic proximity Read ↗

Cytomegalovirus promotes proliferation and survival of prostate cancer cells and constitutes a therapeutic targetSemantic proximity Read ↗

Attenuated multimutated herpes simplex virus-1 effectively treats prostate carcinomas with neural invasion while preserving nerve function.Semantic proximity Read ↗

Oncolytic virotherapy as a novel strategy for pancreatic cancer.Semantic proximity Read ↗

Bacteriophages M13 and T4 Increase the Expression of Anchorage-Dependent Survival Pathway Genes and Down Regulate Androgen Receptor Expression in LNCaP Prostate Cell LineSemantic proximity Read ↗

Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy.Semantic proximity Read ↗

Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.Semantic proximity Read ↗

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.Semantic proximity Read ↗

Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.